Article
Neuroprotection as a therapeutic option for GA
Meeting Abstract
Search Medline for
Authors
Published: | February 5, 2020 |
---|
Outline
Text
Background: Geographic atrophy (GA) is the leading cause of legal blindness in the developed nations with no approved treatment. The current therapeutic focus is on the complement pathway despite several failure.
Methods: Literature review and expert opinion.
Results: Neuroprotection, including photoreceptor protection, can be a therapeutic option for GA. There are extensive pre-clinical to support multiple agents can protect photoreceptor loss in various animal models. There are Phase 2 clinical trial data to support even with photoreceptor protection can slow RPE loss as shown in AF imaging.
Conclusion: It is unclear whether a sub-group of GA might benefit most from neuroprotection.